Exact(2)
Starting at 125 mg, saracatinib doses were assessed sequentially in cohorts of three patients, with dose escalation proceeding to the next dose cohort if no dose-limiting toxicity (DLT) was encountered.
If a dose-limiting toxicity (DLT) was observed in one patient, three additional patients were recruited at that dose level, with dose escalation proceeding if no further DLT occurred at that dose level.
Similar(58)
Dose escalation proceeded without dose-limiting toxicities to a maximum feasible dose of 3 × 109 pfu.
Dose escalation proceeded in the absence of observed DLTs.
If no further DLTs were observed, dose escalation proceeded.
With no further DLT demonstrated in these three consecutive patients, level escalation proceeded.
Dose escalation proceeded until the MTD (800 mg day−1) was determined.
If none of these patients experienced a DLT, then dose escalation proceeded to the next level.
In the absence of DLT, escalation proceeded to the next dose level.
Dose escalation proceeded through all cohorts with no observed DLT attributable to the combination of BelCaP.
If no additional DLTs were observed, escalation proceeded to the next dose level.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com